Raised levels of CD39 in leucocytosis result in marked inhibition of ADP-induced platelet aggregation via rapid ADP hydrolysis

Platelets

Volumn 19, Issue 1, 2008, Pages 59-69

  Glenn, J R ^a,b   White, A E ^a   Johnson, A J ^a   Fox, S C ^a   Myers, B ^b   Heptinstall, S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Adenine nucleotide metabolism; ADP; Leucocyte CD39; Leucocytosis; Platelet aggregation

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; CD39 ANTIGEN; DESULFATOHIRUDIN; HIRUDIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; LEUKEMIA; LEUKOCYTE; LEUKOCYTOSIS; LYMPHOMA; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PROTEIN METABOLISM; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; ANTIGENS, CD; APYRASE; FEMALE; HUMANS; HYDROLYSIS; LEUKOCYTE COUNT; LEUKOCYTES; LEUKOCYTOSIS; MALE; PLATELET AGGREGATION;

EID: 38649139068     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100701665920     Document Type: Article

References (25)

1. Glenn JR, White AE, Johnson A, Fox SC, Behan MWH, Dolan G, Heptinstall S. Leukocyte count and leukocyte ecto-nucleotidase are major determinants of the effects of adenosine triphosphate and adenine diphosphate on platelet aggregation in human blood. Platelets 2005;16:159-170.
2. Coade SB, Pearson JD. Metabolism of adenine nucleotides in human blood. Circ Res 1989;65:531-537.
3. Heptinstall S, Johnson A, Glenn JR, White AE. Adenine nucleotide metabolism in human blood - important roles for leucocytes and erythrocytes. J Thromb Haemost 2005;3:2331-2339.
4. Heptinstall S, Glenn JR, Johnson A, Myers B, White AE, Zhao L. Leukocytosis, vascular disease, and adenine nucleotide metabolism. Atheroscler Thromb Vasc Biol 2006;26:e22-e23.
5. Kansas GS, Wood GS, Tedder TF. Expression, distribution and biochemistry of human CD39. Role in activation associated homotypic adhesion of lymphocytes. J Immunol 1991;146:2235-2244.
6. Koziak K, Sévigny J, Robson SC, Siegel JB, Kaczmarek E. Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leucocytes. Thromb Haemostasis 1999;82:1538-1544.
7. Schlossman SF. Leucocyte typing V: White cell differentiation antigens. Vol. 1. London: Oxford University Press; 1995: 91.
8. Fox SC, Sasae R, Janson S, May JA, Heptinstall S. Quantitation of platelet aggregation and microaggregate formation in whole blood by flow cytometry. Platelets 2004;15:85-93.
9. Hechler B, Cattaneo M, Gachet C. The P2 receptors in platelet function. Semin Thromb Hemost 2005;31:150-161.
10. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999;19:2281-2285.
11. Cattaneo M. The P2 receptors and congenital platelet function defects. Semin Thromb Haemostasis 2005;31:168-173.
12. Nurden AT, Nurden P. Inherited defects of platelet function. Rev Clin Exp Hematol 2001;5:314-334.
13. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y(12) adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005;31:174-183.
14. Heptinstall S. Variable therapeutic effectiveness of clopidogrel in acute coronary syndromes. J Thromb Haemost 2006;4:539-541.
15. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1996;1286:153-181.
16. Leal DBR, Streher CA, Neu TN, Bittencourt FP, Leal CAM, de Silva JEP, Morsch VM, Schetinger MRC. Characterization of NTPDase (NTPDase 1; ecto-apyrase; ecto-diphosphohydrolase; CD39; EC 3.6.1.5) activity in human lymphocytes. Biochim Biophys Acta 2005;1721:9-15.
17. Zatta A, Prosdocimi M, Bertele V, Bazzoni G, Del Maschio A. Inhibition of platelet function by polymorphonuclear leucocytes. J Lab Clin Med 1990;116:651-659.
18. Valles J, Santos MT, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ullman HL, Aznar J. Downregulation of human platelet reactivity by neutrophils. J Clin Invest 1993;92:1357-1365.
19. Salvemini D, De Nucci G, Gryglewski RJ, Vane JR. Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad Sci USA 1989;86:6328-6332.
20. Nicolini FA, Wilson AC, Mehta P, Mehta JL. Comparative platelet inhibitory effects of human neutrophils and lymphocytes. J Lab Clin Med 1990;116:147-151.
21. Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: Mechanisms and treatment. Crit Rev in Oncol Hematol 1995;20:203-222.
22. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 1997;96:111-116.
23. Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk-factors for bleeding and thrombotic complications in myeloproliferative disorders - a retrospective analysis of 260 patients. Ann Hematol 1991;63:101-106.
24. Ganti AK, Potti A, Koda VK, Pervez H, Mehdi SA. Myeloproliferative syndromes and the associated risk of coronary artery disease. Thromb Res 2003;110:83-66.
25. Cukierman T, Gatt ME, Libster D, Goldschmidt N, Matzner Y. Chronic lymphocytic leukemia presenting with extreme hyperleukocytosis and thrombosis of the common femoral vein. Leuk Lymphoma 2002;43:1865-1868.